Evaluation of efficacy and safety of dose-escalating lenalidomide and dexamethasone (Ld) therapy and adapted therapy adding elotuzumab with insufficient efficacy by Ld therapy in newly diagnosed, transplant ineligible multiple myeloma patients (DELAYED study)
Latest Information Update: 05 Apr 2019
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DELAYED
Most Recent Events
- 05 Apr 2019 New trial record